Despite hitting its lowest trading volume since October, Pump.fun’s February figures still rank as the fourth-highest since its launch in 2024.
You might also be interested in reading Sanofi strikes autoimmune drug deal for up to $1.9B.
Despite hitting its lowest trading volume since October, Pump.fun’s February figures still rank as the fourth-highest since its launch in 2024.
You might also be interested in reading Sanofi strikes autoimmune drug deal for up to $1.9B.